BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 26, 2025
See today's BioWorld
Home
» True to its roots, Allergan cuts Exicure hair deal; bid SNAgs big back-end terms
To read the full story,
subscribe
or
sign in
.
True to its roots, Allergan cuts Exicure hair deal; bid SNAgs big back-end terms
Nov. 15, 2019
By
Randy Osborne
CEO David Giljohann said the first indication in
Exicure Inc.
's deal with
Allergan plc
is antigenic alopecia, but his firm doesn't "have anything else to disclose yet" about other hair loss diseases that the pact will include.
BioWorld
Deals and M&A